Active Ingredient History
Fluorescein is a synthetic organic compound available as a dark orange/red powder slightly soluble in water and alcohol. It is widely used as a fluorescent tracer for many applications. Fluorescein was first synthesized by Adolf von Baeyer in 1871. It can be prepared from phthalic anhydride and resorcinol in the presence of zinc chloride via the Friedel-Crafts reaction. Fuorescein sodium is used intravenously in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465-490 nm and fluoresces, i.e., emits light at wavelengths of 520-530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish-green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent areas/structures. Topical, oral, and intravenous use of fluorescein can cause adverse reactions, including nausea, vomiting, hives, acute hypotension, anaphylaxis and related anaphylactoid reaction, causing cardiac arrest and sudden death due to anaphylactic shock. The most common adverse reaction is nausea, due to a difference in the pH from the body and the pH of the sodium fluorescein dye; a number of other factors however, are considered contributors as well. The nausea usually is transient and subsides quickly. Intravenous use has the most reported adverse reactions, including sudden death, but this may reflect greater use rather than greater risk. Both oral and topical uses have been reported to cause anaphylaxis, including one case of anaphylaxis with cardiac arrest (resuscitated) following topical use in an eye drop. Reported rates of adverse reactions vary from 1% to 6%. The higher rates may reflect study populations that include a higher percentage of persons with prior adverse reactions. The risk of an adverse reaction is 25 times higher if the person has had a prior adverse reaction. The risk can be reduced with prior (prophylactic) use of antihistamines and prompt emergency management of any ensuing anaphylaxis. A simple prick test may help to identify persons at greatest risk of adverse reaction NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Iris Diseases (approved 2006)
Retinal Vasculitis (approved 2006)
Accidental Falls (Phase 2)
Adenolymphoma (Phase 2)
Adenomatous Polyps (Phase 1)
Barrett Esophagus (Early Phase 1)
Brain Neoplasms (Phase 4)
Breast Neoplasms (Phase 1/Phase 2)
Cerebrovascular Disorders (Phase 4)
Colonic Polyps (Phase 1)
Dermatology (Phase 2)
Diabetic Retinopathy (Early Phase 1)
Endometrial Neoplasms (Early Phase 1)
Fallopian Tube Neoplasms (Early Phase 1)
Fluorescein Angiography (Phase 4)
Gastroesophageal Reflux (Early Phase 1)
Glioblastoma (Phase 3)
Hamartoma (Early Phase 1)
Heart Septal Defects, Atrial (Phase 1)
Heart Septal Defects, Ventricular (Phase 2)
Hepatitis, Viral, Human (Phase 2)
Hypertrophy, Left Ventricular (Phase 2)
Intestinal Neoplasms (Phase 4)
Irritable Bowel Syndrome (Phase 1)
Liver Cirrhosis (Phase 3)
Macular Degeneration (Early Phase 1)
Neoplasms (Phase 4)
Neuroma, Acoustic (Phase 2)
Non-alcoholic Fatty Liver Disease (Phase 2)
Ovarian Neoplasms (Early Phase 1)
Pharmacokinetics (Phase 1)
Retinal Diseases (Phase 4)
Retinal Vein Occlusion (Early Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Ureteral Diseases (Phase 4)
Urination Disorders (Phase 1)
Vascular Diseases (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
